An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit? / Minssen, Timo; Kesselheim, Aaron; Darrow, Jonathan.
In: Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
AU - Minssen, Timo
AU - Kesselheim, Aaron
AU - Darrow, Jonathan
PY - 2019/1/3
Y1 - 2019/1/3
N2 - A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
AB - A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
U2 - https://doi.org/10.1038/nbt.4324
DO - https://doi.org/10.1038/nbt.4324
M3 - Journal article
VL - 37
SP - 21
EP - 22
JO - Nature Biotechnology
JF - Nature Biotechnology
SN - 1087-0156
IS - 1
ER -
ID: 204531230